ORIGINAL RESEARCH
Accepted on 31 Mar 2025
Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis
doi 10.3389/fimmu.2025.1579859
- Frontiers in Neurology
- Neurological Biomarkers
- Research Topics
- Autoantibodies and autoimmune neuromuscular disorders
Autoantibodies and autoimmune neuromuscular disorders
1,720
Total downloads
6,376
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 24 Mar 2025
Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect
doi 10.3389/fimmu.2025.1549034
- 298 views
CORRECTION
Published on 12 Feb 2025
Corrigendum: Applicability of a serodiagnostic line blot for idiopathic inflammatory myopathy: the muscle biopsy is not all
doi 10.3389/fneur.2025.1567315
- 303 views
ORIGINAL RESEARCH
Published on 06 Jan 2025
Applicability of a serodiagnostic line blot for idiopathic inflammatory myopathy: the muscle biopsy is not all
doi 10.3389/fneur.2024.1504260
- 1,144 views
CASE REPORT
Published on 07 Oct 2024
Case report: target antigen and subclass switch in a patient with autoimmune nodopathy
doi 10.3389/fimmu.2024.1475478
- 918 views
ORIGINAL RESEARCH
Published on 13 Sep 2024
Exhausted signature and regulatory network of NK cells in myasthenia gravis
doi 10.3389/fimmu.2024.1397916
- 1,507 views
- 1 citation
Published in
Frontiers in Neurology
Neurological Biomarkers
Participating Journals
Frontiers in Immunology
- 5.7 impact factor
- 9.8 citescore